Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: Implications for atherogenesis

Clinics

Volumn 64, Issue 5, 2009, Pages 471-478

  Landim, Maurício Batista Paes ^a   Casella Filho, Antônio ^a   Chagas, Antônio Carlos Palandri ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Asymmetric dimethylarginine; Atherogenesis; Cardiovascular risk; Coronary heart disease; Endothelium; Nitric oxide

Indexed keywords

ARGININE; BIOLOGICAL MARKER; DRUG DERIVATIVE; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE; NITRIC OXIDE;

ANIMAL; ATHEROSCLEROSIS; BIOSYNTHESIS; BLOOD; CHRONIC KIDNEY FAILURE; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; ARGININE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; RENAL INSUFFICIENCY, CHRONIC;

EID: 67749120241     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322009000500015     Document Type: Review

References (89)

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007; 357: 1121-35.
2. Murray CJ, Lopez AD. Alternate projections of mortality and disability by cause 1990-2220: global burden of disease study. Lancet. 1997; 349: 1498-504.
3. Vita JA, Keaney Jr. JF. Endothelial function: a barometer for cardiovascular risk? Circulation. 2002; 106: 640-2.
4. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol. 1993;22(suppl 4): S1-S4.
5. Moncada S, Herman AG, Higgs EA, Vane JR. Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the antithrombotic properties of vascular endothelium. Thromb Res. 1977; 11: 323-44.
6. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980; 288: 373-6.
7. Ignarro LJ, Byrns RE, Buga GM, Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res. 1987; 61: 866-79.
8. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987; 327: 524-6.
9. nd ed. Oxford: Oxford University Press; 1999.
10. Ghafourifar P, Cadenas E. Mitochondrial nitric oxide syntase. Trends Pharmacol Sci. 2005; 26: 190-195.
11. Bergendi L, Benes L, Durackova Z, Ferencik, M. Chemistry, physiology and pathology of free radicals. Life Sci. 1999; 65: 1865-74.
12. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. The International Journal of Biochemistry & Cell Biology. 2007; 39: 44-84.
13. Chiueh CC. Neuroprotective properties of nitric oxide. Ann N Y Acad Sci. 1999; 890: 301-11.
14. Kawashima S, Yokoyama, M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2004; 24: 998-1005.
15. Napoli C, Ignarro LJ. Nitric oxide and atheroslcerosis. Nitric Oxide. 2001; 5: 88-97.
16. Bogdan C. Nitric oxide and the immune response. Nat Immunol. 2001; 2: 907-16.
17. Rand MJ. Nitrergic transmission: nitric oxide as a mediator of nonadrenergic, noncholinergic neuro-effector transmission. Clin Exp Pharmacol Physiol. 1992; 19: 147-69.
18. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 2000; 87: 840-4.
19. Kakimoto Y, Akazawa S. Isolation and identification of N-G,N-G- and N-G,N'-G-dimethyl-arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J Biol Chem. 1970; 245: 5751-58.
20. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992; 339: 572-5.
21. Wada K, Inoue K, Hagiwara M. Identification of methylated proteins by protein arginine N-methyltransferase 1, PRMT 1, with a new expression cloning strategy. Biochim Biophys Acta. 2002; 1591: 1-10.
22. Pou S, Keaton L, Surichamom W, Rosen GM. Mechanism of superoxide generation by neuronal nitric oxide synthase. J Biol Chem. 1999; 274: 9573-80.
23. Gardiner SM, Kemp PA, Bennett T, Palmer RM, Moncada S. Regional and cardiac haemodynamic effects of NG, NG, dimethyl-L-arginine and their reversibility by vasodilators in conscious rats. Br J Pharmacol. 1993; 110: 1457-64.
24. Cardounel AJ, Cui H, Samouilov A, Johnson W, Kearns P, Tsai AL, et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J. Biol. Chem. 2007; 282: 879-87.
25. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S, et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol. 2004; 24: 1682-8.
26. +carrier hCAT-2B. Nitric Oxide. 1997; 1: 65-73.
27. Ogawa T, Kimoto M, Watanabe H, Sasaoka K. Metabolism of NG NG- dimethylarginine and NG NG dimethylarginine in rats. Arch Biochem Biophys. 1987; 252: 526-37.
28. Leiper J, MacAllister R, Whitley G, Santa Maria J, Chubb A, Charles I, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology to microbial arginine deiminases. Biochem J. 1999; 343: 209-14.
29. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999; 99: 3092-5.
30. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. 2002;106;987-92.
31. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 2001; 104: 2569-75.
32. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant. 1996; 11: 2449-52.
33. Cross J, Donald A, Vallance P, Deanfield J, Woolfson R, MacAllister R. Dialysis improves endothelial function in humans. Nephrol Dial Transplant. 2001; 16: 1823-9.
34. Hattori Y, Kasai K, Gross SS. Cationic amino acid transporter gene expression in cultured vascular smooth muscle cells and in rats. Am J Physiol. 1999;276:H2020-28.
35. Kimoto M, Whitley GS, Tsuji H, Ogawa T. Detection of NG, NG- dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem. 1995; 117: 237-8.
36. Siroen MP, van der Sijp JR, Teerlink T, van Schaik C, Nijveldt RJ, van Leeuwen PA. The human liver clears both asymmetric and symmetric dimethylarginine. Hepatology. 2005; 41: 559-65.
37. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, et al. Asymmetric dimthylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J. Am. Soc. Nephrol. 2002; 13: 490-96.
38. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358: 2113-17.
39. Yu XJ, Li YJ, Xiong Y. Increase of an endogenous inhibitor of nitric oxide synthesis in serum of high cholesterol fed rabbits. Life Sci. 1994; 54: 753-8.
40. Böger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e) inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000; 20: 1557-64.
41. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998; 98: 1842-7.
42. Päivä H, Laakso J, Lehtimäki T, Isomustajarvi M, Ruokonen I, Laaksonen R. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol. 2003; 41: 219-22.
43. Smirnova IV, Sawamura T, Goligorsky MS. Upregulation of lkectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in endothelial cells by nitric oxide deficiency. Am. J. Physiol. Reanl Physiol. 2004;287:F25-32.
44. Teerlink T. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance. Clin. Chem. Lab. Med. 2005; 43: 1130-8.
45. Päivä H, Lehtimaki T, Laakso J, Ruokonen I, Rantalaibo V, Wirta O, et al. Plasma concentrations of asymmetric-dimethylarginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism. 2003; 52: 303-7.
46. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. 2002; 106: 987-92.
47. Xiong Y, Lei M, Fu S, Fu Y. Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes. Life Sci. 2005; 77: 149-59.
48. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999; 99: 1141-6.
49. Stühlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002; 287: 1420-6.
50. Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke JP, et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism. 2002; 51: 843-6.
51. Mittermayer F, Mayer BX, Meyer A, Winzer C, Pacini G, Wagner OF, et al. Circulating concentrations of asymmetriacal dimethyl-L-arginine are increased in women with previous gestational diabetes. Diabetologia. 2002; 45: 1372-8.
52. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003; 23: 1455-59.
53. Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001;358;2127-28.
54. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J. 2003; 24: 1912-19.
55. Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the influence of ADMA concentration (CARDIAC) study. Am Heart J. 2006;152(3):493.e1-8.
56. Fickling SA, Williams D, Vallance P, Nussey SS, Withley GS. Plasma concentrations of endogenous inhibitor of nitric oxide synthesis in normal pregnancy and pre-eclampsia. Lancet. 1993; 342: 242-243.
57. Savvidou M, Hingorani A, Tsikas D, Frolich J, Vallance P, Nicolaides K. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre ́- eclampsia. Lancet. 2003; 361: 1511-17.
58. Gorenflo M, Zheng C, Werle E, Fiehn W, Hulmer HE. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol. 2001; 37: 489-92.
59. Kielstein JT, Bode-Böger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2005; 25: 1414-18.
60. Petros A, Lamg G, Leone A, Moncada S, Bennett D, Vallance P. Effects of a nitric oxide synthase inhibitor in humans with septick shock. Cardiovasc Res. 1994; 28: 34-9.
61. Paik WK, Kim S. Omega-N-methylarginine in protein. J Biol Chem. 1970; 245: 88-92.
62. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem. 2002; 303: 131-7.
63. Abe T, Tohgi H, Murata T, Isobe C, Sato C. Reduction in asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci Lett. 2001; 312: 177-9.
64. Vishwanathan K, Tackett RL, Stewart JT, Bartlett MG. Determination of arginine and methylated arginines in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl. 2000; 748: 157-66.
65. Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP, et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med. 2004; 42: 1377-83.
66. Boger RH, Bode-Boger SM, Thiele W, Creutzig A, Alexander K, Frolich JK. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol. 1998; 32: 1336-44.
67. Bode-Böger SM, Böger RH, Kienke S, Junker W, Frölich JC. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Bioph Res Comm. 1996; 219: 598-603.
68. Bode-Böger SM, Scalera F, Ignarro LJ. The L-arginine paradox: importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther. 2007; 114:295-306.
69. Napoli C, Sica V, de Nigris F, Pignalosa O, Condorelli M, Ignarro LJ, et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J. 2004;148: e5.
70. Böger RH, Bode-Böger SM, Brandes RP, Phivthong-ngam L, Bohme M, Nafe R, et al. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation. 1997; 96: 1282-90.
71. Jiang JL, Jiang DJ, Tang YH, Li NS, Deng HW, Li YJ. Effect of simvastatin on endothelium-dependent vasorelaxation and endogenous nitric oxide synthase inhibitor. Acta Pharmacol Sin. 2004; 25: 893-901.
72. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol. 2004; 94: 157-61.
73. Yin QF, Xiong Y. Pravastatin restores DDAH activity and endothelium- dependent relaxation of rat aorta after exposure to glycated protein. J Cardiovasc Pharmacol. 2005; 45: 525-32.
74. Janatuiunen T, Laakso J, Laaksonen R, Vesalainen R, Nuutila P, Lehtimaki T, et al. Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults. Vasc Med. 2003; 8: 185-89.
75. Yang TL, Chen MF, Luo BL, Yu J, Jiang JL, Li YJ. Effect of fenofibrate on LDL-induced endothelial dysfunction in rats. Naunyn Schmiedebergs Arch Pharmacol. 2004; 370: 79-83.
76. Dierkes J, Westphal S, Martens-Lobenhoffer J, Luley C, Bode-Böger SM. Fenofibrate increases the L-arginine:ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration. Atherosclerosis. 2004;173: 239-44.
77. Westphal S, Borucki K, Luley C, Martens-Lobenhoffer J, Bode- Böger SM. Treatment with niacin lowers ADMA. Atheroslcerosis. 2006; 184: 448-50.
78. Osanai T, Saitoh M, Sasaki S, Tomita H, Matsunaga T, Okumura K. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension. 2003; 42: 985-90.
79. Wakino S, Hayashi K, Tatematsu S, Hasegawa K, Takamatsu I, Kanda T, et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res. 2005; 28: 255-62.
80. Khan NA, Wiernsperger N, Quemener V, Havouis R, Moulinoux JP. Characterization of metformin transport system in NIH3T3 cells. J Cell Physiol. 1992; 152: 310-16.
81. Jiang L, Li NS, Li YJ, Deng HW. Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Br J Pharmacol. 2002; 135: 1175-82.
82. Saran R, Novak JE, Desai A, Abdulhayoglu E, Warren JS, Bustami R, et al. Impacto f vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study. Nephrol Dial Transplant. 2003; 18: 2415-20.
83. Post MS, Verhoeven MO, van der Mooren MJ, kenemans P, Stehouwer CD, Teerlink T. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women. J Clin Endocrinol Metab. 2003; 88: 4221-26.
84. Verhoeven MO, Hemelaar M, van der Mooren MJ, Kenemans P, Teerlink T. Oral, more than transdrmal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study. J Intern Med. 2006; 259: 199-208.
85. Bode-Böger SM, Martens-Lobenhoffer J, Tager M, Schrö H, Scalera F. Aspirin reduces endothelial cell senescence. Biochem Biophys Res Commun. 2005; 334: 1226-32.
86. Sydow K, Schwedhelm E, Arakawa N, Bode-Böger SM, Tsikas D, Horning B, et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res. 2003; 57: 244-52.
87. Holven KB, Haugstad TS, Holm T, Aukrust P, Ose L, Nenseter MS. Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects. Br J Nutr. 2003; 89:359-63.
88. Scalera F, Kielstein JT, Martens-Lobenhoffer J, Postel SC, Tager M, Bode-Böger SM. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol. 2005; 16: 892-8.
89. Gomes VA, Casella-Filho A, Chagas AC, Tanus-Santos JE. Enhanced concentrations of relevant markers of nitric oxide formation after exercise training in patients with metabolic syndrome. Nitric Oxide. 2008; 19: 345-50.